Annual EBIT
-$25.45 M
+$2.20 M+7.97%
December 31, 2023
Summary
- As of February 7, 2025, CYCC annual earnings before interest & taxes is -$25.45 million, with the most recent change of +$2.20 million (+7.97%) on December 31, 2023.
- During the last 3 years, CYCC annual EBIT has fallen by -$14.82 million (-139.31%).
- CYCC annual EBIT is now -104.78% below its all-time high of $532.00 million, reached on January 1, 1994.
Performance
CYCC EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$2.18 M
+$1.46 M+40.21%
September 30, 2024
Summary
- As of February 7, 2025, CYCC quarterly earnings before interest & taxes is -$2.18 million, with the most recent change of +$1.46 million (+40.21%) on September 30, 2024.
- Over the past year, CYCC quarterly EBIT has increased by +$3.18 million (+59.38%).
- CYCC quarterly EBIT is now -3.08% below its all-time high of -$2.11 million, reached on September 30, 2017.
Performance
CYCC Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$15.53 M
+$4.67 M+23.11%
September 30, 2024
Summary
- As of February 7, 2025, CYCC TTM earnings before interest & taxes is -$15.53 million, with the most recent change of +$4.67 million (+23.11%) on September 30, 2024.
- Over the past year, CYCC TTM EBIT has increased by +$9.92 million (+38.97%).
- CYCC TTM EBIT is now -304.51% below its all-time high of -$3.84 million, reached on March 31, 2003.
Performance
CYCC TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
CYCC EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.0% | +59.4% | +39.0% |
| 3 y3 years | -139.3% | +70.3% | +45.3% |
| 5 y5 years | -166.6% | +70.3% | +45.3% |
CYCC EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -13.7% | +8.0% | at high | +75.4% | at high | +46.3% |
| 5 y | 5-year | -162.9% | +8.0% | at high | +75.4% | -60.4% | +46.3% |
| alltime | all time | -104.8% | +39.1% | -3.1% | +83.8% | -304.5% | +64.1% |
Cyclacel Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.18 M(-40.2%) | -$15.53 M(-23.1%) |
| Jun 2024 | - | -$3.64 M(-16.4%) | -$20.20 M(-10.2%) |
| Mar 2024 | - | -$4.36 M(-18.8%) | -$22.49 M(-11.6%) |
| Dec 2023 | -$25.45 M(-8.0%) | -$5.36 M(-21.7%) | -$25.45 M(-12.0%) |
| Sep 2023 | - | -$6.84 M(+15.4%) | -$28.94 M(+1.3%) |
| Jun 2023 | - | -$5.93 M(-19.0%) | -$28.56 M(+0.5%) |
| Mar 2023 | - | -$7.32 M(-17.3%) | -$28.42 M(+2.7%) |
| Dec 2022 | -$27.66 M(+23.5%) | -$8.85 M(+36.8%) | -$27.66 M(+11.5%) |
| Sep 2022 | - | -$6.47 M(+11.8%) | -$24.80 M(+1.9%) |
| Jun 2022 | - | -$5.79 M(-11.8%) | -$24.33 M(-1.3%) |
| Mar 2022 | - | -$6.56 M(+9.6%) | -$24.64 M(+10.1%) |
| Dec 2021 | -$22.39 M(+110.5%) | -$5.99 M(-0.2%) | -$22.39 M(+14.4%) |
| Sep 2021 | - | -$6.00 M(-1.7%) | -$19.57 M(+21.2%) |
| Jun 2021 | - | -$6.10 M(+41.7%) | -$16.14 M(+29.0%) |
| Mar 2021 | - | -$4.30 M(+35.9%) | -$12.52 M(+17.7%) |
| Dec 2020 | -$10.64 M(+9.9%) | -$3.17 M(+23.2%) | -$10.64 M(+3.6%) |
| Sep 2020 | - | -$2.57 M(+4.0%) | -$10.26 M(+2.2%) |
| Jun 2020 | - | -$2.47 M(+2.0%) | -$10.04 M(+1.4%) |
| Mar 2020 | - | -$2.42 M(-13.2%) | -$9.90 M(+2.3%) |
| Dec 2019 | -$9.68 M(+1.4%) | -$2.79 M(+19.0%) | -$9.68 M(+3.5%) |
| Sep 2019 | - | -$2.35 M(+0.5%) | -$9.35 M(-1.1%) |
| Jun 2019 | - | -$2.34 M(+6.0%) | -$9.46 M(-1.3%) |
| Mar 2019 | - | -$2.20 M(-10.6%) | -$9.59 M(+0.4%) |
| Dec 2018 | -$9.55 M(+0.6%) | -$2.46 M(+0.4%) | -$9.55 M(+2.9%) |
| Sep 2018 | - | -$2.46 M(-0.4%) | -$9.28 M(+3.8%) |
| Jun 2018 | - | -$2.46 M(+14.0%) | -$8.94 M(-0.3%) |
| Mar 2018 | - | -$2.16 M(-1.6%) | -$8.96 M(-5.6%) |
| Dec 2017 | -$9.49 M(-32.9%) | -$2.20 M(+4.1%) | -$9.49 M(-9.3%) |
| Sep 2017 | - | -$2.11 M(-15.1%) | -$10.46 M(-11.5%) |
| Jun 2017 | - | -$2.49 M(-7.6%) | -$11.83 M(-9.7%) |
| Mar 2017 | - | -$2.69 M(-15.0%) | -$13.10 M(-7.4%) |
| Dec 2016 | -$14.15 M(-12.5%) | -$3.17 M(-8.9%) | -$14.15 M(-4.7%) |
| Sep 2016 | - | -$3.48 M(-7.5%) | -$14.84 M(+0.6%) |
| Jun 2016 | - | -$3.76 M(+0.4%) | -$14.76 M(+1.0%) |
| Mar 2016 | - | -$3.74 M(-3.0%) | -$14.62 M(-9.6%) |
| Dec 2015 | -$16.17 M(-27.9%) | -$3.86 M(+13.8%) | -$16.17 M(-10.6%) |
| Sep 2015 | - | -$3.39 M(-6.2%) | -$18.09 M(-11.2%) |
| Jun 2015 | - | -$3.62 M(-31.7%) | -$20.37 M(-8.8%) |
| Mar 2015 | - | -$5.30 M(-8.4%) | -$22.32 M(-0.5%) |
| Dec 2014 | -$22.44 M(+24.8%) | -$5.78 M(+2.0%) | -$22.44 M(+8.8%) |
| Sep 2014 | - | -$5.67 M(+1.7%) | -$20.63 M(-0.6%) |
| Jun 2014 | - | -$5.58 M(+3.0%) | -$20.75 M(+7.4%) |
| Mar 2014 | - | -$5.41 M(+36.1%) | -$19.33 M(+11.9%) |
| Dec 2013 | -$17.97 M | -$3.97 M(-31.4%) | -$17.28 M(-5.9%) |
| Sep 2013 | - | -$5.79 M(+39.5%) | -$18.37 M(+13.8%) |
| Jun 2013 | - | -$4.15 M(+23.8%) | -$16.15 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$3.36 M(-33.8%) | -$15.50 M(+1.6%) |
| Dec 2012 | -$15.11 M(-0.4%) | -$5.07 M(+41.9%) | -$15.26 M(+10.3%) |
| Sep 2012 | - | -$3.57 M(+1.9%) | -$13.84 M(+1.2%) |
| Jun 2012 | - | -$3.51 M(+12.6%) | -$13.67 M(-1.2%) |
| Mar 2012 | - | -$3.12 M(-14.5%) | -$13.84 M(-10.7%) |
| Dec 2011 | -$15.17 M(-2.2%) | -$3.64 M(+7.1%) | -$15.50 M(+10.4%) |
| Sep 2011 | - | -$3.40 M(-7.5%) | -$14.05 M(-3.7%) |
| Jun 2011 | - | -$3.68 M(-23.0%) | -$14.59 M(-3.2%) |
| Mar 2011 | - | -$4.78 M(+118.3%) | -$15.06 M(-2.8%) |
| Dec 2010 | -$15.50 M(-23.8%) | -$2.19 M(-44.5%) | -$15.51 M(-12.8%) |
| Sep 2010 | - | -$3.94 M(-5.1%) | -$17.79 M(+3.8%) |
| Jun 2010 | - | -$4.15 M(-20.4%) | -$17.13 M(-15.4%) |
| Mar 2010 | - | -$5.22 M(+16.8%) | -$20.24 M(-0.5%) |
| Dec 2009 | -$20.34 M(-51.4%) | -$4.47 M(+35.9%) | -$20.34 M(-17.3%) |
| Sep 2009 | - | -$3.29 M(-54.7%) | -$24.60 M(-29.2%) |
| Jun 2009 | - | -$7.26 M(+36.7%) | -$34.75 M(-6.9%) |
| Mar 2009 | - | -$5.31 M(-39.1%) | -$37.31 M(-10.5%) |
| Dec 2008 | -$41.82 M(+35.0%) | -$8.73 M(-35.1%) | -$41.68 M(-3.7%) |
| Sep 2008 | - | -$13.44 M(+36.8%) | -$43.29 M(+17.7%) |
| Jun 2008 | - | -$9.83 M(+1.5%) | -$36.78 M(+10.0%) |
| Mar 2008 | - | -$9.68 M(-6.3%) | -$33.43 M(+10.3%) |
| Dec 2007 | -$30.98 M(-6.5%) | -$10.34 M(+49.0%) | -$30.30 M(+13.4%) |
| Sep 2007 | - | -$6.94 M(+7.2%) | -$26.72 M(+1.7%) |
| Jun 2007 | - | -$6.47 M(-1.3%) | -$26.27 M(-5.9%) |
| Mar 2007 | - | -$6.56 M(-2.9%) | -$27.93 M(-15.7%) |
| Dec 2006 | -$33.14 M(+59.5%) | -$6.75 M(+4.1%) | -$33.14 M(+4.6%) |
| Sep 2006 | - | -$6.49 M(-20.2%) | -$31.69 M(+9.4%) |
| Jun 2006 | - | -$8.13 M(-30.9%) | -$28.96 M(+9.4%) |
| Mar 2006 | - | -$11.77 M(+121.6%) | -$26.47 M(+27.4%) |
| Dec 2005 | -$20.77 M(-21.6%) | -$5.31 M(+41.3%) | -$20.77 M(-10.7%) |
| Sep 2005 | - | -$3.76 M(-33.3%) | -$23.25 M(-11.8%) |
| Jun 2005 | - | -$5.63 M(-7.3%) | -$26.36 M(-1.8%) |
| Mar 2005 | - | -$6.08 M(-22.0%) | -$26.85 M(+1.3%) |
| Dec 2004 | -$26.51 M(+48.6%) | -$7.79 M(+13.5%) | -$26.51 M(+12.9%) |
| Sep 2004 | - | -$6.86 M(+12.0%) | -$23.48 M(+14.3%) |
| Jun 2004 | - | -$6.13 M(+6.8%) | -$20.55 M(+4.1%) |
| Mar 2004 | - | -$5.74 M(+20.6%) | -$19.73 M(+10.6%) |
| Dec 2003 | -$17.84 M(-9.2%) | -$4.76 M(+21.1%) | -$17.84 M(+36.4%) |
| Sep 2003 | - | -$3.93 M(-26.0%) | -$13.08 M(+42.9%) |
| Jun 2003 | - | -$5.31 M(+38.3%) | -$9.15 M(+138.3%) |
| Mar 2003 | - | -$3.84 M | -$3.84 M |
| Dec 2002 | -$19.64 M(-1.2%) | - | - |
| Dec 2001 | -$19.88 M(+46.5%) | - | - |
| Dec 2000 | -$13.56 M(-102.5%) | - | - |
| Jan 1994 | $532.00 M(+23.8%) | - | - |
| Jan 1993 | $429.80 M | - | - |
FAQ
- What is Cyclacel Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual EBIT year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly EBIT year-on-year change?
- What is Cyclacel Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals TTM EBIT year-on-year change?
What is Cyclacel Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of CYCC is -$25.45 M
What is the all time high annual EBIT for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual earnings before interest & taxes is $532.00 M
What is Cyclacel Pharmaceuticals annual EBIT year-on-year change?
Over the past year, CYCC annual earnings before interest & taxes has changed by +$2.20 M (+7.97%)
What is Cyclacel Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of CYCC is -$2.18 M
What is the all time high quarterly EBIT for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly earnings before interest & taxes is -$2.11 M
What is Cyclacel Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, CYCC quarterly earnings before interest & taxes has changed by +$3.18 M (+59.38%)
What is Cyclacel Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of CYCC is -$15.53 M
What is the all time high TTM EBIT for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high TTM earnings before interest & taxes is -$3.84 M
What is Cyclacel Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, CYCC TTM earnings before interest & taxes has changed by +$9.92 M (+38.97%)